Education
About Us
Working with TipRanks
Follow Us
Allergy Therapeutics PLC (GB:AGY)
LSE:AGY
AGY Stock Chart & Stats
11.80p
-0.04p(-0.55%)
At close: 4:00 PM EST
11.80p
-0.04p(-0.55%)
Day’s Range― - ―
52-Week Range5.00p - 10.90p
Previous CloseN/A
Volume22.64K
Average Volume (3M)460.33K
Market Cap
£690.91M
Enterprise Value426.23M
Total Cash (Recent Filing)£12.79M
Total Debt (Recent Filing)£60.09M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding6,141,440,000
10 Day Avg. Volume433,490
30 Day Avg. Volume460,334
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)-13.44
Price to Sales (P/S)6.88
P/FCF Ratio-11.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Allergy Therapeutics News
AGY FAQ
What was Allergy Therapeutics PLC’s price range in the past 12 months?
Allergy Therapeutics PLC lowest share price was 5.00p and its highest was 10.90p in the past 12 months.
What is Allergy Therapeutics PLC’s market cap?
Allergy Therapeutics PLC’s market cap is £690.91M.
When is Allergy Therapeutics PLC’s upcoming earnings report date?
Allergy Therapeutics PLC’s upcoming earnings report date is Feb 26, 2026 which is in 62 days.
How were Allergy Therapeutics PLC’s earnings last quarter?
Allergy Therapeutics PLC released its earnings results on Dec 11, 2025. The company reported -0.006p earnings per share for the quarter, missing the consensus estimate of -0.005p by -0.001p.
Is Allergy Therapeutics PLC overvalued?
According to Wall Street analysts Allergy Therapeutics PLC’s price is currently Overvalued.
Does Allergy Therapeutics PLC pay dividends?
Allergy Therapeutics PLC does not currently pay dividends.
What is Allergy Therapeutics PLC’s EPS estimate?
Allergy Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Allergy Therapeutics PLC have?
Allergy Therapeutics PLC has 6,141,440,000 shares outstanding.
What happened to Allergy Therapeutics PLC’s price movement after its last earnings report?
Allergy Therapeutics PLC reported an EPS of -0.006p in its last earnings report, missing expectations of -0.005p. Following the earnings report the stock price went down -0.463%.
Which hedge fund is a major shareholder of Allergy Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AGY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allergy Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
Allergy Therapeutics PLC
Allergy Therapeutics (AGY) is a biotechnology company focused on the development and commercialization of innovative allergy immunotherapy products. The company specializes in providing treatments for allergic conditions, primarily targeting pollen, dust mites, and animal allergens. Its core product offerings include allergy vaccines and immunotherapy solutions designed to alleviate symptoms and improve the quality of life for patients suffering from allergies. AGY operates primarily within the healthcare sector, leveraging cutting-edge research to develop effective therapies for allergy sufferers worldwide.
Technical Analysis
Animalcare
―
Hikma Pharmaceuticals
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―
Options Prices
Currently, No data available
---